About Jasper Therapeutics
Jasper Therapeutics is a company based in Redwood City (United States) founded in 1999 by Judith Shizuru and Susan Prohaska. Jasper Therapeutics has raised $84.1 million across 3 funding rounds from investors including Roche, ARE and Citadel. Jasper Therapeutics operates in a competitive market with competitors including BridgeBio, Moderna, Forge Biologics, Spark Therapeutics and Mereo BioPharma, among others.
- Headquarter Redwood City, United States
- Founders Judith Shizuru, Susan Prohaska
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$84.1 M (USD)
in 3 rounds
-
Latest Funding Round
$14.1 M (USD), Series A
Jan 09, 2020
-
Investors
Roche
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Jasper Therapeutics
Jasper Therapeutics has successfully raised a total of $84.1M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $14.1 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $14.1M
-
First Round
First Round
(06 Dec 2019)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2020 | Amount | Series A - Jasper Therapeutics | Valuation | Roche |
|
| Dec, 2019 | Amount | Series A - Jasper Therapeutics | Valuation |
investors |
|
| Dec, 2019 | Amount | Series A - Jasper Therapeutics | Valuation | Qiming , Abingworth |
Investors in Jasper Therapeutics
Jasper Therapeutics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, ARE and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare companies are funded by Qiming, a venture capital firm.
|
Founded Year | Domain | Location | |
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Jasper Therapeutics
Financial Statements - Jasper Therapeutics
Jasper Therapeutics Comparisons
Competitors of Jasper Therapeutics
Jasper Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Moderna, Forge Biologics, Spark Therapeutics and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases are developed to treat patients.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
Frequently Asked Questions about Jasper Therapeutics
Jasper Therapeutics was founded in 1999 and raised its 1st funding round 20 years after it was founded.
Jasper Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Ronald Martell is the current CEO of Jasper Therapeutics.
Jasper Therapeutics is a funded company, having raised a total of $84.1M across 3 funding rounds to date. The company's 1st funding round was a Series A of $35M, raised on Dec 06, 2019.
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells. It offers Briquilimab a targeted anti c-Kit monoclonal antibody to deplete mast cells and diseased stem cells for chronic urticaria and lower to intermediate risk myelodysplastic syndromes.
Jasper Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Jasper Therapeutics has 5 investors. Key investors include Roche, ARE, Citadel, Abingworth, and Qiming.